Revenue

6 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Revenue

Revenue

Disaggregation of Revenue by Product

MiMedx has two primary classes of products: (1) Advanced Wound Care, or Section 361, products, consisting of its sheet allograft products, and (2) Section 351 products, consisting of the Company’s micronized and particulate products. Advanced Wound Care is further disaggregated between the Company’s Tissue/Other and Cord products.

Below is a summary of net sales by each class of product (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Advanced Wound Care
Tissue/Other	$	53,408	$	42,528	$	99,977	$	87,134
Cord	5,886		3,263		10,846		7,160
Total Advanced Wound Care	59,294		45,791		110,823		94,294
Section 351	8,558		6,150		16,698		14,888
Other(1)	313		1,706		611		6,201
Total	$	68,165	$	53,647	$	128,132	$	115,383

(1) “Other” represents cash collections on the Remaining Contracts. Remaining Contracts are those contracts for which performance obligations have been satisfied as of September 30, 2019, but for which the criteria required for revenue recognition had not been met and would not be met until the ultimate collection of cash. For all practicable purposes, the Company is not able to allocate these revenues to different product groups.

Disaggregation of Revenue by Customer

MiMedx has two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (“Direct Customers”), and (2) sales through distributors (“Distributors”).

Below is a summary of net sales by each customer type (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Direct Customers	$	66,061	$	52,755	$	123,619	$	112,651
Distributors	2,104		892		4,513		2,732
Total	$	68,165	$	53,647	$	128,132	$	115,383

The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three or six months ended June 30, 2021 or 2020.